A macrophage-targeted TIMD4 Peptide-Nanoparticle attenuates colitis symptoms and monocyte recruitment in a mouse model

What To Know

This PLOS Biology abstract reports a preclinical mouse study testing a TIMD4-derived peptide delivered in macrophage-targeted nanoparticles (T4(365–378)-NPs).

In dextran sulfate sodium (DSS) colitis models, genetic loss of Timd4 worsened inflammation and increased monocyte recruitment, while treatment with the peptide-nanoparticles reduced NF-κB signaling (P65 phosphorylation) and improved colitis measures.

The peptide-NPs had similar effects to a CCR2 antagonist, and combining the peptide-NPs with anti-α4β7 or anti-TNF-α antibodies produced larger improvements than either antibody alone in the mouse model.

The report is preclinical and focused on mechanism: TIMD4 appears to stabilize an LKB1-STRAD-MO25 complex to activate AMPK and suppress NF-κB–driven chemokine production in macrophages. The authors propose further preclinical evaluation of TIMD4-derived peptide delivery as a potential therapeutic strategy for intestinal inflammation.

The study does not report human clinical data or clinical dosing; it is an animal/mechanistic study testing an investigational peptide delivered by nanoparticles and comparing effects to a CCR2 antagonist and to biologic antibodies in mice.